Nicole E Benfante

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6082372/publications.pdf

Version: 2024-02-01

52	867	16	26
papers	citations	h-index	g-index
53	53	53	1382
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. European Urology Oncology, 2021, 4, 532-539.	5.4	75
2	The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. European Urology Focus, 2019, 5, 104-108.	3.1	58
3	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2020, 203, 1122-1127.	0.4	58
4	Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 259.e1-259.e8.	1.6	56
5	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. European Urology Focus, 2017, 3, 421-427.	3.1	43
6	Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. European Urology, 2018, 73, 53-59.	1.9	41
7	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. European Urology, 2021, 79, 468-477.	1.9	35
8	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clinical Genitourinary Cancer, 2019, 17, 373-379.e4.	1.9	33
9	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European Urology Focus, 2017, 3, 590-598.	3.1	31
10	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	7.0	30
11	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. Journal of Urology, 2020, 203, 1117-1121.	0.4	28
12	Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. Journal of Sexual Medicine, 2019, 16, 872-879.	0.6	27
13	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 532.e7-532.e13.	1.6	25
14	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 35.e1-35.e5.	1.6	21
15	Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens. European Urology, 2018, 73, 488-490.	1.9	20
16	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	5.4	20
17	Clinical Findings and Treatment Outcomes in Patients with Extraprostatic Extension Identified on Prostate Biopsy. Journal of Urology, 2016, 196, 703-708.	0.4	17
18	The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma. Journal of Urology, 2016, 195, 264-269.	0.4	15

#	Article	IF	Citations
19	Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 603.e1-603.e5.	1.6	15
20	Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. European Urology Focus, 2018, 4, 100-105.	3.1	14
21	Development and Validation of the Satisfaction Survey for Inflatable Penile Implant (SSIPI). Journal of Sexual Medicine, 2021, 18, 1641-1651.	0.6	14
22	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Modern Pathology, 2022, 35, 825-835.	5 . 5	14
23	Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. World Journal of Urology, 2017, 35, 51-56.	2.2	13
24	Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically. World Journal of Urology, 2016, 34, 539-544.	2.2	12
25	Nephrometry scores and perioperative outcomes following robotic partial nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 1075-1083.	1.5	11
26	Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 257-263.	2.2	11
27	Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e9-530.e14.	1.6	10
28	Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. European Urology Oncology, 2020, 3, 365-371.	5.4	10
29	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
30	Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. Journal of Urology, 2017, 198, 546-551.	0.4	8
31	A Randomized, Controlled, 3-Arm Trial of Pharmacological Penile Rehabilitation in the Preservation of Erectile Function After Radical Prostatectomy. Journal of Sexual Medicine, 2021, 18, 423-429.	0.6	8
32	Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. European Journal of Surgical Oncology, 2022, 48, 1427-1432.	1.0	8
33	Importance of long-term follow-up after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management. International Urology and Nephrology, 2020, 52, 1465-1469.	1.4	7
34	Bother Associated with Climacturia After Radical Prostatectomy: Prevalence and Predictors. Journal of Sexual Medicine, 2020, 17, 731-736.	0.6	7
35	Primary urethral cancer: treatment patterns and associated outcomes. BJU International, 2020, 126, 359-366.	2.5	7
36	The association of renal cell carcinoma with gastrointestinal stromal tumors. Journal of Surgical Oncology, 2018, 117, 1716-1720.	1.7	6

#	Article	IF	CITATIONS
37	Preoperative nomogram predicting 12-year probability of metastatic renal cancer $\hat{a} \in \text{``evaluation'}$ in a contemporary cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 853.e1-853.e7.	1.6	6
38	Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Journal of Urology, 2021, 205, 400-406.	0.4	6
39	The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy. Sexual Medicine, 2021, 9, 100378-100378.	1.6	5
40	The Relationship Between PSA and Total Testosterone Levels in Men with Prostate Cancer. Journal of Sexual Medicine, 2022, 19, 471-478.	0.6	5
41	Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?. Journal of Urology, 2018, 199, 1502-1509.	0.4	4
42	Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical) Tj ETQq0 0 0 rgBT /0197-200.	Overlock 10 1.0	0 Tf 50 547 T 4
43	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e17-791.e24.	1.6	3
44	Estimating patient health in prostate cancer treatment counseling. Prostate Cancer and Prostatic Diseases, 2023, 26, 271-275.	3.9	3
45	Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Journal of Urology, 2022, 207, 1222-1226.	0.4	3
46	Routine Postoperative Hemoglobin Assessment Poorly Predicts Transfusion Requirement among Patients Undergoing Minimally Invasive Radical Prostatectomy. Urology Practice, 2020, 7, 299-304.	0.5	2
47	The association between modifiable perioperative parameters and renal function after nephrectomy. BJU International, 2022, 129, 380-386.	2.5	2
48	Shared Medical Appointments for Prostate Cancer Active Surveillance Followup Visits. Urology Practice, 2021, 8, 541-545.	0.5	2
49	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. Journal of Urology, 2020, 204, 460-465.	0.4	2
50	Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 495.e17-495.e24.	1.6	1
51	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. Bladder Cancer, 2022, 8, 291-301.	0.4	1
52	Reply by Authors. Journal of Urology, 2020, 203, 1121-1121.	0.4	0